biostudies-literatureUnknown20(29)Brufsky APfizer<b>Aim</b>: Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer.<b>Materials & methods</b>: A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics, treatment perceptions and other clinical/nonclinical characteristics.<b>Results</b>: Efficacy and safety/tolerability were critical in oncologists' 1L decision-making. CDK4/6i use positively correlated with proportion of Medicare and postmenopausal patients (r = 0.54-0.67). Chemotherapy use demonstrated positive correlations with perimenopausal and premenopausal patients and symptom burden (r = 0.31-0.42). Aromatase inhibitor (AI) monotherapy correlated positively with anticipated treatment compliance (r = 0.42).<b>ConclusionFuture oncology (London, England)2165-2177https://www.ebi.ac.uk/biostudies/studies/S-EPMC11508941biostudies-literatureIdentifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices.PMC11508941Kopenhafer LKurosky SKOlsen PHeck WArruda LSBrufsky ACha-Silva ASMaculaitis MCfalseIdentifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices.<b>Aim</b>: Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer.<b>Materials & methods</b>: A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics, treatment perceptions and other clinical/nonclinical characteristics.<b>Results</b>: Efficacy and safety/tolerability were critical in oncologists' 1L decision-making. CDK4/6i use positively correlated with proportion of Medicare and postmenopausal patients (r = 0.54-0.67). Chemotherapy use demonstrated positive correlations with perimenopausal and premenopausal patients and symptom burden (r = 0.31-0.42). Aromatase inhibitor (AI) monotherapy correlated positively with anticipated treatment compliance (r = 0.42).<b>Conclusion2024-01-01T00:00:00Z20242025-04-06T09:38:29.114Z2025-04-06T09:38:29.114ZS-EPMC115089413886129510.1080/14796694.2024.2350294